A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
KYNTRA BIO, INC.
KYNB
$28M
Mkt Cap
$7.03
-0.57%
KYNTRA BIO, INC. (KYNB) has a current P/E ratio of 0.1.
KYNTRA BIO, INC. (KYNB) has a 5-year average return on invested capital (ROIC) of -62.4%. This is below average and may indicate limited pricing power.
KYNTRA BIO, INC. (KYNB) has a market capitalization of $28M. It is classified as a small-cap stock.
KYNTRA BIO, INC. (KYNB) does not currently pay a regular dividend.
KYNTRA BIO, INC. (KYNB) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
KYNTRA BIO, INC. (KYNB) generated $-5 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
KYNTRA BIO, INC. (KYNB) reported earnings per share (EPS) of $45.37 in its most recent fiscal year.
FibroGen, Inc. (“FibroGen”) is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. We are developing FG-3246, a potential first-in-class antibody-drug conjugate (“ADC”) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (“mCRPC”) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (“PET”) biomarker and imaging agent. We anticipate initiation of a Phase 2 monotherapy dose optimization study of FG-3246 for the treatment of mCRPC in mid-2025. We and our collaboration partners have developed roxadustat (爱瑞卓®, EVRENZOTM), which is currently approved in the People’s Republic of China (“China”), Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease patients on dialysis and not on dialysis.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | 30M | - | - | 235M |
| Net Income | 183M | 183M | -48M | -284M | -294M | -290M |
| EPS | $45.37 | $45.37 | $-297.25 | $-73.00 | $-78.50 | $-78.50 |
| Free Cash Flow | -4.8M | -4.8M | -138M | -318M | -150M | -87M |
| ROIC | -549.1% | -38.4% | -70.1% | -76.2% | -39.0% | -88.3% |
| Gross Margin | - | - | 47.5% | - | - | 94.5% |
| Debt/Equity | 0.00 | -2.87 | -0.39 | -0.91 | -4.21 | 0.48 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | -46M | -46M | -150M | -323M | -301M | -289M |
| Operating Margin | 0.0% | - | -507.8% | - | - | -122.6% |
| ROE | 0.0% | -143.5% | 22.1% | 252.0% | -312.9% | -91.9% |
| Shares Outstanding | 4M | 4M | 0M | 4M | 4M | 4M |
| Metric | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 138M | 181M | 183M | 131M | 213M | 257M | 176M | 235M | N/A | N/A | 30M | N/A | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A | 99.6% | 95.0% | 94.5% | N/A | N/A | 47.5% | N/A | N/A |
| R&D | 151M | 214M | 187M | 197M | 236M | 209M | 253M | 387M | 297M | 266M | 96M | 24M | 24M |
| SG&A | 37M | 44M | 46M | 52M | 64M | 135M | 106M | 124M | 125M | 86M | 49M | 28M | 28M |
| EBIT | -50M | -78M | -50M | -117M | -87M | -89M | -192M | -289M | -301M | -323M | -150M | -46M | -46M |
| Op. Margin | -36.4% | -42.9% | -27.3% | -89.5% | -40.7% | -34.8% | -108.8% | -122.6% | N/A | N/A | -507.8% | N/A | 0.0% |
| Net Income | -60M | -86M | -58M | -121M | -86M | -77M | -189M | -290M | -294M | -284M | -48M | 183M | 183M |
| Net Margin | -43.2% | -47.4% | -31.7% | -92.3% | -40.6% | -30.0% | -107.4% | -123.3% | N/A | N/A | -160.6% | N/A | 0.0% |
| Non-Recurring | 10K | -98K | 0 | -3K | -53K | 42K | -933K | -233K | 1K | 14M | 17M | 553K | 553K |
| Returns on Capital | |||||||||||||
| ROIC | -73.7% | -42.9% | -26.9% | -27.5% | -15.2% | -14.5% | -37.8% | -88.3% | -39.0% | -76.2% | -70.1% | -38.4% | N/M |
| ROE | -74.1% | -43.0% | -34.8% | -35.3% | -16.7% | -15.0% | -40.3% | -91.9% | -312.9% | 252.0% | 22.1% | -143.5% | 0.0% |
| ROA | -24.6% | -18.0% | -12.4% | -17.7% | -9.7% | -8.9% | -22.5% | -36.2% | -42.4% | -55.0% | -14.9% | 109.8% | 153.4% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 22M | -19M | 7.1M | -67M | -76M | -79M | 82M | -82M | -146M | -315M | -138M | -4.8M | -4.8M |
| Free Cash Flow | 14M | -21M | 5.9M | -75M | -84M | -84M | 78M | -87M | -150M | -318M | -138M | -4.8M | -4.8M |
| Owner Earnings | -754K | -52M | -31M | -110M | -135M | -156M | -2.8M | -164M | -222M | -375M | -166M | -12M | -12M |
| CapEx | 8.1M | 2.0M | 1.3M | 8.5M | 8.0M | 5.8M | 4.0M | 5.2M | 3.7M | 2.5M | 266K | 38K | 38K |
| Maint. CapEx | 4.5M | 5.7M | 6.0M | 6.1M | 6.6M | 11M | 12M | 10M | 10M | 9.5M | 2.7M | 713K | 713K |
| Growth CapEx | 3.6M | 0 | 0 | 2.4M | 1.5M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| D&A | 4.5M | 5.7M | 6.0M | 6.1M | 6.6M | 11M | 12M | 10M | 10M | 9.5M | 2.7M | 713K | 713K |
| CapEx/OCF | 36.2% | N/A | 17.6% | N/A | N/A | N/A | 4.9% | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 19M | 28M | 32M | 38M | 52M | 66M | 73M | 71M | 66M | 51M | 25M | 6.6M | 6.6M |
| Debt Repayment | 0 | 0 | 403K | 403K | 403K | 403K | 403K | 403K | 403K | 336K | 0 | 0 | 0 |
| Balance Sheet | |||||||||||||
| Net Debt | -179M | -287M | -204M | -638M | -621M | -482M | -647M | -304M | -332M | -18M | 37M | -2.7M | 38M |
| Cash & Equiv. | 165M | 153M | 174M | 674M | 89M | 126M | 678M | 171M | 156M | 82M | 50M | 48M | 48M |
| Long-Term Debt | 403K | 403K | 97M | 98M | 0 | 38M | 25M | 3K | 137K | 72M | 73M | 75M | 75M |
| Debt/Equity | 0.00 | 0.00 | 0.62 | 0.18 | 0.00 | 0.10 | 0.09 | 0.48 | -4.21 | -0.91 | -0.39 | -2.87 | 0.00 |
| Interest Coverage | -4.5 | -7.0 | -4.7 | -12.1 | -7.9 | -31.1 | -79.9 | -268.4 | -209.0 | -39.9 | -18.2 | -5.2 | -5.2 |
| Equity | 221M | 178M | 156M | 528M | 509M | 516M | 422M | 209M | -21M | -204M | -226M | -30M | -30M |
| Total Assets | 484M | 471M | 470M | 899M | 881M | 857M | 827M | 774M | 610M | 424M | 215M | 120M | 120M |
| Total Liabilities | 243M | 274M | 294M | 351M | 352M | 322M | 385M | 545M | 612M | 606M | 419M | 128M | 128M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0 | 0 |
| Retained Earnings | -322M | -452M | -510M | -631M | -716M | -785M | -974M | -1.3B | -1.6B | -1.8B | -1.9B | -1.7B | -1.7B |
| Working Capital | 135M | 133M | 201M | 663M | 601M | 600M | 592M | 249M | 219M | 114M | 63M | 70M | 70M |
| Current Assets | 198M | 201M | 267M | 749M | 690M | 702M | 755M | 474M | 493M | 332M | 197M | 99M | 99M |
| Current Liabilities | 63M | 67M | 65M | 86M | 89M | 103M | 163M | 225M | 274M | 218M | 133M | 29M | 29M |
| Per Share Data | |||||||||||||
| EPS | -25.19 | -35.50 | -23.25 | -41.50 | -25.75 | -22.25 | -52.75 | -78.50 | -78.50 | -73.00 | -297.25 | 45.37 | 45.37 |
| Owner EPS | -0.32 | -21.49 | -12.44 | -37.82 | -40.18 | -45.13 | -0.78 | -44.27 | -59.23 | -96.39 | -1,036.26 | -2.98 | -2.98 |
| Book Value | 93.74 | 73.48 | 62.40 | 181.44 | 151.72 | 149.20 | 117.65 | 56.61 | -5.73 | -52.44 | -1,409.45 | -7.43 | -7.43 |
| Cash Flow/Share | 9.49 | -7.69 | 2.85 | -22.84 | -22.69 | -22.75 | 22.74 | -22.26 | -39.01 | -80.91 | -862.15 | -1.18 | 45.55 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 2.4M | 2.4M | 2.5M | 2.9M | 3.4M | 3.5M | 3.6M | 3.7M | 3.7M | 3.9M | 0.2M | 4.0M | 4.0M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.2 |
| P/FCF | 112.8 | N/A | 222.3 | N/A | N/A | N/A | 45.0 | N/A | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | 2.3 | 10.2 | 8.4 | 6.7 | 7.4 | 7.5 | 8.3 | 6.4 | N/A | N/A | N/A | N/A | N/A |
| Price/Sales | 3.5 | 8.7 | 6.8 | 20.0 | 20.8 | 15.4 | 20.6 | 9.1 | N/A | N/A | 3.3 | N/A | N/A |
| FCF Yield | 2.8% | -1.1% | 0.4% | -2.1% | -2.2% | -2.2% | 2.2% | -6.6% | -10.5% | -358.9% | -240.5% | N/A | -16.9% |
| Market Cap | 512M | 1.8B | 1.3B | 3.5B | 3.8B | 3.9B | 3.5B | 1.3B | 1.4B | 88M | 57M | 0 | 28M |
| Avg. Price | 639.29 | 654.42 | 484.39 | 898.98 | 1,320.82 | 1,140.62 | 1,014.28 | 580.44 | 327.38 | 250.09 | 24.42 | 0.00 | 7.03 |
| Year-End Price | 682.50 | 752.00 | 521.25 | 1,218.75 | 1,120.75 | 1,122.25 | 972.75 | 360.50 | 382.50 | 22.73 | 14.50 | 0.00 | 7.03 |
KYNTRA BIO, INC. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 71.0%. At current prices, the estimated annualized return to fair value is -6.2%.
KYNTRA BIO, INC. (KYNB) has a return on equity (ROE) of -143.5%. A negative ROE may indicate losses or negative equity.
KYNTRA BIO, INC. (KYNB) has a 5-year average gross margin of 71.0%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 13 years of financial data for KYNTRA BIO, INC. (KYNB), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
KYNTRA BIO, INC. (KYNB) has a book value per share of $-7.43, based on its most recent annual SEC filing.